Education & Career

• 1988 B.S. College of Pharmacy, Chungbuk National University, Korea
  
• 1990 M.S. College of Pharmacy, Chungbuk National University, Korea
  
• 1996 Ph.D. Graduate Center for Toxicology, Univ. of Kentucky, U.S.A
  
• 1990-2001 Senior Researcher, Korea Food and Drug Administration (KFDA), Korea
  
• 2002-2005 Adjunct Researcher, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Korea
  
• 2002-present Advisory Board Member, (Functional Food, Cosmetic and Drug), Korea Food and Drug Administration (KFDA), Korea
  
• 2007-2008 Visiting Scholar, University of Kentucky, U.S.A
  
• 2008-present Director, Medical Research Center, Korea
  
• 2011-2018 Director, Bio-Valley for Academy-Industry Convergence in Osong
  
• 2019-present Dean, College of Pharmacy, Chungbuk National University
  
• 1995-present Member, Society of Toxicology, U.S.A
  
• 1995-present Member, American Association for Cancer Research, U.S.A
  
• 2008-present Editoial Board Member, Journal of Medicinal Food, Journal of Alzheimer's Disease
  
• 2005-present Vice President, The Korean Society of Toxicogenomics and Toxico- proteomics, Korea
  
• 2015-present Vice president, The Korean Society of Applied Pharmacology, Korea
  
• 2015-2016 Chief of Academic Committee, The Pharmaceutical Society of Korea
  
• 2017-2018 Secretary General, The Pharmaceutical Society of Korea

International Collaboration

• 2007. 7: Univ. of London, UK (Prof. Ivan Gout, PRDX6)
  
• 2001. 1: Univ. of Kentucky, USA (Prof. Howard P. Glauert, Carcinogenesis)
  
• 2008. 9: Univ. of Kentucky, USA (Prof. Kyng Bo Kim, Chemical design for STAT3)
  
• 2010. 1: Stany Research Institute, USA (Dr. Sang Hyun Kim, Anxiety, Alzheimer’s disease)

Research Areas

1. 함암작용 및 치료제 개발 연구

2. 신경계질환 (치매, 파킨손, 우울증 등) 원인 규명 및 치료제 개발

Selected Publications

1. Lee DH, Jung YY, Park MH, Jo MR, Yoon DY, Han SB, Roh YS, Hong JT. Peroxiredoxin 6 confers protection against non-alcoholic fatty liver disease through maintaining mitochondrial function. Antioxid Redox Signal. 2019 Apr 22.
2. Yeo IJ, Park MH, Son DJ, Kim JY, Nam KT, Hyun BK, Kim SY, Jung MH, Song MJ, Chun HO, Lee TH, Han SB, Hong JT. PRDX6 Inhibits Neurogenesis through Downregulation of WDFY1-Mediated TLR4 Signal. Mol Neurobiol. 2019 May;56(5):3132-31445:
3. Park KR, Yun HM, Yeo IJ, Cho S, Hong JT*, Jeong YS. Peroxiredoxin 6 Inhibits Osteogenic Differentiation and Bone Formation Through Human Dental Pulp Stem Cells and Induces Delayed Bone Development. Antioxid Redox Signal. 2019 Jun 10;30(17):1969-1982.
4. Kim KC, Yun J, Son DJ, Kim JY, Jung JK, Choi JS, Kim YR, Song JK, Kim SY, Kang SK, Shin DH, Roh YS, Han SB, Hong JT. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. Theranostics. 2018 Aug 7;8(16):4409-4428.
5. Son DJ, Zheng J, Jung YY, Hwang CJ, Lee HP, Woo JR, Baek SY, Ham YW, Kang MW, Shong M, Kweon GR, Song MJ, Jung JK, Han SB, Kim BY, Yoon DY, Choi BY, Hong JT. MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity via Direct Binding to the STAT3 DNA-Binding Domain. Theranostics 7.18 (2017): 4632
6. Jung YY, Kim KC, Park MH, Seo Y, Park H, Park MH, Chang J, Hwang DY, Han SB, Kim S, Son DJ, Hong JT.. Atherosclerosis is exacerbated by chitinase-3-like-1 in amyloid precursor protein transgenic mice. Theranostics 8.3 (2018): 749
7. Yun J, Park MH, Son DJ, Nam KT, Moon DB, Ju JH, Hwang OK, Choi JS, Kim TH, Jung YS, Hwang DY, Han SB, Yoon DY, Hong JT. IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation. Cell death & disease 9.3 (2018): 306
8. Lee YS, Lee CH, Bae JT, Nam KT, Moon DB, Hwang OK, Choi JS, Kim TH, Jun HO,Jung YS, Hwang DY, Han SB, Yoon DY, Hong JT. Inhibition of skin carcinogenesis by suppression of NF-κB dependent ITGAV and TIMP-1 expression in IL-32γ overexpressed condition. J Exp Clin Cancer Res. 2018 Nov 28;37(1):293. :
9. Lee YS, Jung YY, Park MH, Yeo IJ, Im HS, Nam KT, Kim HD, Kang SK, Song JK, Kim YR, Choi DY, Park PH, Han SB, Yun JS, Hong JT. Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination. Cancer Lett. 2018 Oct 1;433:156-164
10. Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin 32, inflammation and cancer. Pharmacol Ther. 2017 Jun;174:127-137

Patents

1. [미국]2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀 및 이의 제조방법(2018.12 등록)
2. [미국]2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀의 항암치료제 약제학적 조성물 (2019.3 등록)
3. [미국]2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀의 관절염 및 항염증 질환 치료제 약제학적 조성물 (2019.4 등록)
4. [중국]2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀 및 이의 제조방법(2017.09.30 출원)
5. [중국]2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀을 유효성분으로 함유하는 염증성질환 또는 관절염치료 예방용 약학적 조성물(2017.09.30 출원)
6. [중국]2-메톡시-4(3-4(4-메톡시페닐프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물 (2017.10.10 출원)

Education & Career

• 2008.4.1 – 2012.3.26 Ph.D. Graduate school of Medicine NAGOYA UNIVERSITY, JAPAN
• 1999.3.2 – 2001.2.24 M.S. College of Pharmacy CHUNGBUK NATIONAL UNIVERSITY, REPUBLIC OF KOREA
• 1995.3.2 – 1999.2.25 B.S. College of Pharmacy CHUNGBUK NATIONAL UNIVERSITY, REPUBLIC OF KOREA
• 2018.9.1- present Professor, Chungbuk National University, REPUBLIC OF KOREA
• 2017.3.1 - 2018.8.31 Professor, Wonkwang University, REPUBLIC OF KOREA
• 2012.4.1- 2012.11.3O POST DOC fellowship, Graduate school of Medicine NAGOYA UNIVERSITY, JAPAN
• 2004.5.10 – 2017.2.28 SCIENTIFIC RESEARCHER, MINISTRY OF FOOD AND DRUG SAFETY, NATIONAL INSTITUTE OF FOOD AND DRUG SAFETY EVALUATION, REPUBLIC OF KOREA

Research Areas

1. 약물 의존성 형성의 기전 및 타겟 분자 규명 연구
   
   
2. 스트레스 반응 분자 규명 및 정신질환 상관성 연구
   

Selected Publications

1. Methoxetamine Induces Cytotoxicity in H9c2 Cells: Possible Role of p21 Protein (Cdc42/Rac)-Activated Kinase 1. Yoon KS, Gu SM, Lamichhane S, Han KM, Shin J, Kim YH, Suh SK, Cha HJ, Yun J. Cardiovasc Toxicol. 2019 Jun;19(3)
2. 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo. Yoon KS, Yun J, Kim YH, Shin J, Kim SJ, Seo JW, Hyun SA, Suh SK, Cha HJ. Toxicol Lett. 2019 Apr;304:50-57.
3. Limonene Inhibits Methamphetamine-Induced Sensitizations via the Regulation of Dopamine Receptor Supersensitivity. Gu SM, Kim SY, Lamichhane S, Hong JT, Yun J. Biomol Ther (Seoul). 2019 Feb 8
4. Receptor Binding Affinities of Synthetic Cannabinoids Determined by Non-Isotopic Receptor Binding Assay. Cha HJ, Song YJ, Lee DE, Kim YH, Shin J, Jang CG, Suh SK, Kim SJ, Yun J. Toxicol Res. 2019 Jan;35(1):37-44
5. Lee YS, Jung YY, Park MH, Yeo IJ, Im HS, Nam KT, Kim HD, Kang SK, Song JK, Kim YR, Choi DY, Park PH, Han SB, Yun JS, Hong JT. Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination. Cancer Lett. 2018 Oct 1;433:156-164.
6. Kim KC, Yun J, Son DJ, Kim JY, Jung JK, Choi JS, Kim YR, Song JK, Kim SY, Kang SK, Shin DH, Roh YS, Han SB, Hong JT. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. Theranostics. 2018 Aug 7;8(16):4409-4428.
7. Kim SY, Lamichhane S, Ju JH, Yun J Protective Effect of Octylmethoxycinnamate against UV-Induced Photoaging in Hairless Mouse via the Regulation of Matrix metalloproteinases. Int J Mol Sci. 2018 Jun 22;19(7).
8. Gu SM, Lee HP, Ham YW, Son DJ, Kim HY, Oh KW, Han SB, Yun J, Hong JT Piperlongumine Improves Lipopolysaccharide-Induced Amyloidogenesis by Suppressing NF-KappaB Pathway. Neuromolecular Med. 2018 Sep;20(3):312-327.
9. Yun J, Yeo IJ, Hwang CJ, Choi DY, Im HS, Kim JY, Choi WR, Jung MH, Han SB, Hong JT. Estrogen deficiency exacerbates Aβ-induced memory impairment through enhancement of neuroinflammation, amyloidogenesis and NF-ĸB activation in ovariectomized mice. Brain Behav Immun. 2018 Oct;73:282-293.
10. Kim S, Choi KH, Yun J. Exploration of alternative test methods to evaluate phototoxicity of ophthalmic agents by using Statens Seruminstitut Rabbit Cornea cell lines and 3D human reconstituted cornea models. PLoS One. 2018 May 21;13(5):e0196735
11. Yun J, Park MH, Son DJ, Nam KT, Moon DB, Ju JH, Hwang OK, Choi JS, Kim TH, Jung YS, Hwang DY, Han SB, Yoon DY, Hong JT IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation. Cell Death Dis. 2018 Feb 21;9(3):306
12. Gu SM, Lee HJ, Lee TH, Song YJ, Kim YH, Han KM, Shin J, Park HK, Kim HS, Cha HJ, Yun J. A synthetic cannabinoid JWH-210 reduces lymphoid organ weights and T-cell activator levels in mice via CB2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2017 Dec;390(12):1201-1209
13. Yun J, Lee KW, Eom JH, Kim YH, Shin J, Han K, Park HK, Kim HS, Cha HJ Potential for Dependence on Lisdexamfetamine - In vivo and In vitro Aspects. Biomol Ther (Seoul). 2017 Nov 1;25(6):659-664
14. Yun J, Gu SM, Lee TH, Song YJ, Seong S, Kim YH, Cha HJ, Shin J, Oh H, Jung K, Ahn C, Park HK, Kim HS. Synthetic cannabinoid-induced immunosuppression augments cerebellar dysfunction in tetanus-toxin treated mice. Biomolecules & Therapeutics. 2016. Nov 25, i: 10.4062/biomolther.2016.11.6
15. Yun J, Yoon KS, Lee T, Lee H, Gu SM, Song YJ, Cha HJ, Han KM, Seo H, Shin J, Park H, Kim HS, Kim Y. Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicol. Res., 2016, 5, 1663-1671 Sep,7
16. Yun J, Kim SY, Yoon KS, Shin H, Jeong HS, Chung H, Kim YH, Shin J, Cha HJ, Han KM, Hyeon S, Lee TH, Park HK, Kim HS. P21 (Cdc42/Rac)-activated kinase 1 (pak1) is associated with cardiotoxicity induced by antihistamines. Arch Pharm Res. 2016 12. 39(12): 1644-1652.
17. Yun J, Oliynyk S, Lee Y, Kim J, Yun K, Jeon R, Ryu J, Oh S. Ajoene restored behavioral patterns and liver glutathione level in morphine treated C57BL6 mice. Arch Pharm Res. 2017

Patents

1. Therapeutic Agent for Drug Abuse and Addiction Comprising L-THP as Active Ingredient, Patent No. 1010540930000. Jul. 28, 2011
2. Therapeutic Agent for Drug Abuse and Addiction Comprising Baicalein as Active Ingredient, Patent No. 1008043120000. Feb. 11, 2008
3. Therapeutic Agent for Drug Abuse and Addiction Comprising Baicalin as Active ingredient, Patent No. 1008043110000. Feb. 11, 2008
4. Anodynes with Reduced Drug Addiction, Patent No. 1007794190000. Nov. 20, 2007
5. Therapeutic Agent for Drug Abuse and Addiction Comprising Saikosaponin A as Active Ingredient, Patent No. 1007499310000. Aug. 17, 2007
6. Therapeutic Agent for Narcotics Addiction, Patent No. 1007159390000. May. 2, 2007